Divi's Laboratories Limited (NSE:DIVISLAB)
6,636.00
-62.00 (-0.93%)
May 28, 2025, 3:29 PM IST
Divi's Laboratories Employees
Divi's Laboratories had 9,741 employees as of March 31, 2024. The number of employees increased by 1,308 or 15.51% compared to the previous year.
Employees
9,741
Change (1Y)
1,308
Growth (1Y)
15.51%
Revenue / Employee
9.61M INR
Profits / Employee
2.25M INR
Market Cap
1,761.65B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 9,741 | 1,308 | 15.51% |
Mar 31, 2023 | 8,433 | -8,110 | -49.02% |
Mar 31, 2022 | 16,543 | -275 | -1.64% |
Mar 31, 2021 | 16,818 | 2,934 | 21.13% |
Mar 31, 2020 | 13,884 | 2,037 | 17.19% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Sun Pharmaceutical Industries | 43,000 |
Cipla | 27,764 |
Apollo Hospitals Enterprise | 83,147 |
Mankind Pharma | 19,540 |
Zydus Lifesciences | 26,921 |
Aurobindo Pharma | 26,015 |
Alkem Laboratories | 17,432 |
Fortis Healthcare | 12,088 |
Divi's Laboratories News
- 2 days ago - Morgan Stanley maintains overweight on Divis Labs, sees 11% upside after second global order win - Business Upturn
- 4 days ago - Divis Laboratories signs long-term supply deal with global pharma company - Business Upturn
- 8 days ago - BHEL, Hyundai & more: Top stocks on brokers' radar today - The Times of India
- 9 days ago - Stocks in news today: Divis Labs, Delhivery, Premier Energies, Zen Tech, KRBL, Galaxy Surfactants, Kaynes Tech after Q4 earnings on May 19 - Business Upturn
- 3 months ago - Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... - GuruFocus
- 3 months ago - Q3 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 4 months ago - Divi’s Labs remains our top pick, target price at Rs 6,850 after Q3 results: Citi - Business Upturn
- 6 months ago - Citi reaffirms ‘Buy’ on Divi’s Laboratories, sees buying opportunities amid BioSecure delays - Business Upturn